Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Clinical-trial"

1112 News Found

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers


SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
News | August 27, 2021

SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate

The company has to approach the DCGI for approval to commence the trials


Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
Biotech | August 17, 2021

Suven Life Sciences announces Phase 3 clinical trial of Masupirdine

This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024


China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne


Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Drug Approval | August 02, 2021

Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients

Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine


Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19
News | June 30, 2021

Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19

The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India


COVAXIN phase II/III clinical trial approved for 2-18 years
News | May 13, 2021

COVAXIN phase II/III clinical trial approved for 2-18 years

BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years


Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
News | May 08, 2026

Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push

The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities


Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
News | May 07, 2026

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy


Parexel's acquisition of Vitrana boosts AI capabilities for patient safety solutions
Clinical Trials | May 06, 2026

Parexel's acquisition of Vitrana boosts AI capabilities for patient safety solutions

AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance